JP2023510350A5 - - Google Patents
Info
- Publication number
- JP2023510350A5 JP2023510350A5 JP2022542336A JP2022542336A JP2023510350A5 JP 2023510350 A5 JP2023510350 A5 JP 2023510350A5 JP 2022542336 A JP2022542336 A JP 2022542336A JP 2022542336 A JP2022542336 A JP 2022542336A JP 2023510350 A5 JP2023510350 A5 JP 2023510350A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- complex according
- exon
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025172493A JP2026012197A (ja) | 2020-01-10 | 2025-10-14 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959796P | 2020-01-10 | 2020-01-10 | |
| US62/959,796 | 2020-01-10 | ||
| US202062965748P | 2020-01-24 | 2020-01-24 | |
| US62/965,748 | 2020-01-24 | ||
| US202062968443P | 2020-01-31 | 2020-01-31 | |
| US62/968,443 | 2020-01-31 | ||
| US202062980874P | 2020-02-24 | 2020-02-24 | |
| US62/980,874 | 2020-02-24 | ||
| US202063055537P | 2020-07-23 | 2020-07-23 | |
| US63/055,537 | 2020-07-23 | ||
| US202063069066P | 2020-08-23 | 2020-08-23 | |
| US63/069,066 | 2020-08-23 | ||
| US202063132929P | 2020-12-31 | 2020-12-31 | |
| US63/132,929 | 2020-12-31 | ||
| PCT/US2021/012756 WO2021142307A1 (en) | 2020-01-10 | 2021-01-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025172493A Division JP2026012197A (ja) | 2020-01-10 | 2025-10-14 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510350A JP2023510350A (ja) | 2023-03-13 |
| JP2023510350A5 true JP2023510350A5 (https=) | 2024-01-22 |
| JP7780691B2 JP7780691B2 (ja) | 2025-12-05 |
Family
ID=76788858
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542336A Active JP7780691B2 (ja) | 2020-01-10 | 2021-01-08 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| JP2025172493A Pending JP2026012197A (ja) | 2020-01-10 | 2025-10-14 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025172493A Pending JP2026012197A (ja) | 2020-01-10 | 2025-10-14 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230111212A1 (https=) |
| EP (1) | EP4087878A4 (https=) |
| JP (2) | JP7780691B2 (https=) |
| KR (1) | KR20220125802A (https=) |
| CN (1) | CN115335401A (https=) |
| AU (1) | AU2021205346A1 (https=) |
| BR (1) | BR112022013572A2 (https=) |
| IL (1) | IL294478A (https=) |
| MX (1) | MX2022008540A (https=) |
| WO (1) | WO2021142307A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| AU2021206234A1 (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
| WO2022270585A1 (ja) | 2021-06-23 | 2022-12-29 | 日本新薬株式会社 | アンチセンスオリゴマーの組み合わせ |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| AU2022309238A1 (en) * | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP2024525611A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| JP2024525608A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US20240390508A1 (en) * | 2021-08-21 | 2024-11-28 | Takeda Pharmaceutical Company Limited | Human transferrin receptor binding peptide-drug conjugate |
| EP4401777A4 (en) * | 2021-09-16 | 2025-08-13 | Dyne Therapeutics Inc | DOSAGE OF MUSCLE-TARGETING COMPLEXES TO TREAT DYSTROPHINOPATHIES |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| EP4612185A1 (en) * | 2022-10-31 | 2025-09-10 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for skipping exon 45 of a dmd gene |
| EP4702143A2 (en) | 2023-04-24 | 2026-03-04 | BioMarin Pharmaceutical Inc. | Compositions and methods for treating stxbp1 disorders |
| CN120648680A (zh) * | 2024-03-15 | 2025-09-16 | 迦进生物医药(上海)有限公司 | 治疗杜兴型肌营养不良症和贝克型肌营养不良症的药物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| SI1461359T1 (sl) * | 2002-01-18 | 2007-06-30 | Pf Medicament | Nova anti IGF-IR protitelesa in njihova uporaba |
| JP5931720B2 (ja) * | 2009-05-08 | 2016-06-08 | クルナ・インコーポレーテッド | Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療 |
| WO2012091718A1 (en) * | 2010-12-30 | 2012-07-05 | Cedars-Sinai Medical Center | Polymalic acid-based nanobiopolymer compositions and methods for treating cancer |
| BR112014020826A8 (pt) * | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
| US10508151B2 (en) * | 2014-11-19 | 2019-12-17 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| MX2019008199A (es) * | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| AU2018378812B2 (en) * | 2017-12-06 | 2025-05-22 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
| IL312067B2 (en) * | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
| WO2021142331A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease |
| KR20220125801A (ko) * | 2020-01-10 | 2022-09-14 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
| AU2021206234A1 (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CA3163608A1 (en) * | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle-targeting complexes and uses thereof |
| WO2021142217A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Thereapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of milck1 |
| WO2021142260A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of acvr1 |
| CA3163283A1 (en) * | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
| WO2021142269A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy |
| CN115427059A (zh) * | 2020-01-31 | 2022-12-02 | 达因疗法公司 | 抗转铁蛋白受体（tfr）抗体及其用途 |
| WO2022270585A1 (ja) * | 2021-06-23 | 2022-12-29 | 日本新薬株式会社 | アンチセンスオリゴマーの組み合わせ |
-
2021
- 2021-01-08 JP JP2022542336A patent/JP7780691B2/ja active Active
- 2021-01-08 BR BR112022013572A patent/BR112022013572A2/pt unknown
- 2021-01-08 IL IL294478A patent/IL294478A/en unknown
- 2021-01-08 WO PCT/US2021/012756 patent/WO2021142307A1/en not_active Ceased
- 2021-01-08 EP EP21738534.3A patent/EP4087878A4/en active Pending
- 2021-01-08 MX MX2022008540A patent/MX2022008540A/es unknown
- 2021-01-08 CN CN202180019467.9A patent/CN115335401A/zh active Pending
- 2021-01-08 KR KR1020227027138A patent/KR20220125802A/ko active Pending
- 2021-01-08 AU AU2021205346A patent/AU2021205346A1/en active Pending
- 2021-01-08 US US17/791,701 patent/US20230111212A1/en active Pending
-
2025
- 2025-10-14 JP JP2025172493A patent/JP2026012197A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023510350A5 (https=) | ||
| JP2024527362A5 (https=) | ||
| JP2023535073A5 (https=) | ||
| JP2023509793A5 (https=) | ||
| JP2024525610A5 (https=) | ||
| JP2021532831A5 (https=) | ||
| JP2024525611A5 (https=) | ||
| JP2024525612A5 (https=) | ||
| JP2023512441A5 (https=) | ||
| Hudson | Recombinant antibody fragments | |
| Beiboer et al. | Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent | |
| JP2024525613A5 (https=) | ||
| JP6420813B2 (ja) | 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）Ｐｓｌ結合分子およびその使用 | |
| JP2023512442A5 (https=) | ||
| JP2023511774A5 (https=) | ||
| JP2024540199A5 (https=) | ||
| JP2023510351A5 (https=) | ||
| JP7663977B2 (ja) | 抗ｐｄ―ｌ１抗体およびその用途 | |
| IL309936A (en) | Muscle targeting complexes and formulations for the treatment of dystrophinopathy | |
| JP2024524222A5 (https=) | ||
| JP2011509245A5 (https=) | ||
| JP2008542278A5 (https=) | ||
| AU2016304060A1 (en) | Antibody against glypican-3 and application thereof | |
| JP2010511388A5 (https=) | ||
| JP2023549537A5 (https=) |